Tagged: microbiome
18 results
Geoffrey von Maltzahn
Geoffrey von Maltzahn is the co-founder and CEO of Lila Sciences, a Cambridge company building what it calls scientific superintelligence: AI plus robotic labs that run the scientific method autonomously. A general partner at Flagship Pioneering, he has founded or co-founded a string of companies including Generate:Biomedicines, Tessera Therapeutics, Indigo Agriculture, Sana Biotechnology, Seres Therapeutics and Quotient Therapeutics, which together carry more than $10 billion in market value. He holds a PhD from the Harvard-MIT Division of Health Sciences and Technology and is named on more than 200 patents.
Louis Licamele
Louis Licamele, PhD is a computer scientist turned drug developer who serves as Chief Development Officer and EVP of Clinical and Data Science at Bloom Science, a San Diego biotech building microbiome-based, ketogenic-mimicking live biotherapeutics for obesity and neurological disease. A founding team member, he oversees biostatistics, clinical data management, and data-driven trial design for the company's lead candidate BL-001. He built his career at the intersection of data and medicine - a BS in biology and computer science from Georgetown, a PhD in computer science from the University of Maryland, and senior informatics and biometrics roles at Vanda Pharmaceuticals and REGENXBIO. He also runs The Licamele Group, advising healthcare companies on data science, AI, and regulatory strategy.
Matt Barnard
Matt Barnard is the cofounder and CEO of one.bio, a Sacramento biotechnology company turning plant fiber into odorless, tasteless nutrients that can be dosed into everyday food to reshape the gut microbiome. A seventh-generation Wisconsin farmer turned technology operator, he first became known as the cofounder and CEO of Plenty, the SoftBank-backed indoor vertical farming unicorn. He now applies the same obsession - control what people eat, control their health - to fiber science spun out of UC Davis.
Tezza Foods
Tezza Foods makes the first dairy-free yogurt that goes spoon-for-spoon with Greek yogurt. By culturing and straining organic American-grown soymilk, the Oakland-based company turns whole soybeans into a thick, high-protein yogurt with the protein and probiotics of dairy Greek yogurt - plus fiber and omega-3s - using about 90% less land, water and emissions than dairy. Founded in 2019 by MIT-trained microbiome scientist Nathaniel Chu and Josh Moser, Tezza is a public benefit corporation built on the idea that the world's most nutritious and sustainable protein should be the one we all eat.
Concerto Biosciences
Concerto Biosciences is a Cambridge, Massachusetts microbiome company that turns microbial ecology into health products. Its patented kChip platform screens millions of microbial interactions in nanoliter droplets to discover 'ensembles' - small, defined groups of microbes that work together to shepherd a damaged microbial community back to health. The company's lead program, ENS-002, is a topical live biotherapeutic for atopic dermatitis that suppresses Staphylococcus aureus without nuking the skin's helpful microbes. Founded in 2020 by scientists out of MIT and the Broad Institute, Concerto pairs ultra-high-throughput biology with AI to make microbial communities predictable and engineerable.
Cheri Ackerman Araromi
Cheri Ackerman Araromi is the cofounder and CEO of Concerto Biosciences, a Cambridge, Massachusetts biotech that reads the social lives of microbes the way a producer reads a band. Using kChip, a droplet screening platform she helped build during her postdoc at the Broad Institute, Concerto tests how thousands of microbial combinations interact and assembles the winning ensembles into products for skin health, agriculture, and beyond. A Hertz Fellow with a Berkeley PhD in chemical biology, she frames the future of medicine as building healthy ecosystems rather than killing bad cells with toxins.
Cheryl Sew Hoy
Cheryl Sew Hoy is a serial entrepreneur and the founder and CEO of Tiny Health, an Austin-based microbiome science company that raised an $8.5M Series A in 2024. Born in Malaysia and trained as an engineer at Cornell, she sold her startup Reclip.It to Walmart Labs in 2013, then was recruited to run MaGIC, Malaysia's national innovation agency. She co-founded the #MovingForward campaign for diversity in venture capital and was named one of Time's 2017 Silence Breakers, the magazine's Person of the Year.
Christopher Reyes
Christopher Reyes is a biophysicist turned serial biotech entrepreneur and the CEO, co-founder, and director of Bloom Science, a San Diego company developing living medicines that harness the gut-brain axis. Bloom's lead program, BL-001, is a first-in-class oral live biotherapeutic designed to replicate the anti-seizure effects of the ketogenic diet, built on technology licensed from UCLA. With a PhD in biophysics from UCSF and a track record that includes a fast-acquired cancer startup, Reyes is betting that genetically optimized gut bacteria can treat pharmacoresistant neurological diseases.
Vivek Lal
Dr. C. Vivek Lal is a physician-scientist turned founder who runs resbiotic, a Birmingham-based wellness company building clinically tested probiotic and prebiotic supplements on a 'Gut-X Axis' platform. A double board-certified neonatologist who directs the Pulmonary Microbiome Lab at the University of Alabama at Birmingham, Lal turned more than 100 peer-reviewed papers and NIH-funded lab work into a string of companies, including the drug-development firm Alveolus Bio and the pediatric chain Urgent Care for Children. In September 2025, resbiotic closed an $8 million Series A, bringing its total funding to $14.5 million.
one.bio
one.bio is a Sacramento biotechnology company that releases short-chain plant fibers and makes them flavorless, odorless, colorless and water-soluble so they can be added to food and drinks at high doses without changing taste or texture. Spun out of UC Davis, it pairs a fiber-mapping knowledgebase called the Glycopedia with a proprietary depolymerization process to turn long-chain plant carbohydrates - including agricultural byproducts - into bioactive fibers that feed the microbiome and support metabolic and immune health. The company raised a $27M Series A in December 2024 and in early 2026 launched its discovery platform, its first clinically validated ingredient (one.bio 01) and a consumer brand, GoodVice.
Bloom Science, Inc.
Bloom Science is a San Diego clinical-stage biotech translating the biology of the ketogenic diet into oral live biotherapeutics that act through the gut-immune-brain axis. Built on microbiome research licensed from UCLA and powered by its IrisRx discovery platform, the company is developing BL-001, a once-daily bacterial therapy being studied in obesity and in drug-resistant seizures from Dravet syndrome, with a pipeline reaching toward ALS and neurodegenerative disease.
resbiotic
resbiotic is a physician-founded microbiome health company building clinically tested probiotics, prebiotics, postbiotics, and bioactive botanicals around its Gut-X Axis platform - the idea that the gut talks to the rest of the body. Its flagship resB Lung Support is positioned as the first clinically tested probiotic targeting the gut-lung axis for respiratory health. Founded in 2020 by physician-scientist Dr. C. Vivek Lal out of microbiome research at the University of Alabama at Birmingham, the company sells direct-to-consumer and through retail including Walmart and GNC, and has raised roughly $20.6M to date.
Biohm Technologies
Biohm Technologies is a Cleveland-based microbiome innovation company that studies the gut as a whole - bacteria and fungi together - rather than bacteria alone. Built on 40+ years of fungal research by Dr. Mahmoud Ghannoum, the scientist who named the mycobiome, Biohm develops data-driven biotic ingredients and gut-health testing solutions. Its flagship ingredient Mycohsa is the first probiotic blend clinically shown to break down digestive biofilms, and its Symbiont discovery platform mines a large bacterial-fungal dataset to design targeted microbiome products. After a B2B pivot in 2024, the company now sells ingredients and microbiome science to nutraceutical and food brands.
Sam Schatz
Sam Schatz is the CEO and co-founder of Biohm Technologies, a Cleveland-based microbiome company betting that the future of gut health lives in fungi, not just bacteria. After spending a decade as AeroFarms' first employee scaling vertical farming from a startup into a global leader, he pivoted to the gut, turning a direct-to-consumer wellness brand into a B2B ingredients and data company built on a proprietary dataset of bacterial and fungal gut populations. He pairs data science with biology, raised a $4.52M Series B in 2025, and shipped Mycohsa, a probiotic blend clinically shown to break down digestive biofilms. Off the clock he is an Adirondack 46er and open-water swimmer.
OLIPOP
OLIPOP is a prebiotic soda company that turned the soft drink industry on its head by proving that soda can be both delicious and good for your gut. Founded in 2018 by Ben Goodwin and David Lester, the Oakland-based company combines nostalgic flavors with functional ingredients - each can delivers 6-9 grams of prebiotic fiber from plant-based sources like cassava root, chicory root, and nopal cactus. After reaching $400 million in revenue and profitability in 2024, OLIPOP closed a $50 million Series C at a $1.85 billion valuation in 2025, making it the fastest-growing non-alcoholic beverage brand in the United States.
Chris Abbott
Chris Abbott is the Chief Executive Officer of Pivot Bio, a Berkeley-based agricultural biotechnology company pioneering microbial nitrogen solutions that replace synthetic fertilizers. A Minnesota native and University of Minnesota graduate, Abbott built his career at the intersection of agriculture finance and agtech investing - from Wall Street sell-side research at Piper Jaffray to co-leading Continental Grain's Conti Ventures. He joined Pivot Bio's board in 2018, and in August 2023 stepped up as CEO, guiding the company past $100 million in annual revenue while scaling its gene-edited microbes to over 5 million acres. Under his leadership, Pivot Bio achieved 60% year-over-year revenue growth and has helped farmers reduce synthetic nitrogen use by over 129,000 metric tons.
Mohan Iyer
Mohan Iyer is a General Partner at SOSV's IndieBio SF, the world's leading biotech accelerator. With 25+ years operating life science startups across Genentech, Tethys Bioscience, Second Genome, and Pendulum Therapeutics, he brings rare bench-to-boardroom experience to pre-seed biotech founders. Trained as a chemical and biomedical engineer before earning his MBA from Yale, Iyer has spent his career translating disruptive biology into products the world actually needs — and now bets on founders doing the same.
Stuart Peterson
Stuart Peterson is the Founder and Managing General Partner of ARTIS Ventures, a San Francisco-based venture capital firm he launched in 2001 that coined and trademarked the term 'TechBio.' A 2017 Forbes Midas List honoree, Peterson led early-stage investments in YouTube (acquired by Google) and StemCentrx (acquired by AbbVie for $10.2 billion - the largest-ever venture-backed life sciences acquisition), and has since focused ARTIS at the convergence of computer science and life science, closing a $200 million TechBio II Fund in December 2023 to back next-generation health and medicine companies deploying AI, machine learning, and deep learning to transform human health.